VERA THERAPEUTICS INC CLASS A (VERA)
Health Care · Autoimmune kidney disease therapeutics · NASDAQ
Vera Therapeutics is developing atacicept, a first-in-class B-cell modulator targeting both BAFF and APRIL for autoimmune kidney diseases including IgAN, pending FDA decision in July 2026.
What VERA THERAPEUTICS INC CLASS A does
Vera Therapeutics is a biotechnology company developing transformative treatments for patients with serious immunological and autoimmune kidney diseases. The company's lead product candidate, atacicept, is a native human TACI-Fc fusion protein that binds both BAFF and APRIL cytokines and is being evaluated for immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. Atacicept is self-administered subcutaneously at home as an autoinjector, and the company submitted a Biologics License Application to the FDA in November 2025 with a priority review PDUFA target action date of July 7, 2026.
Themes: ["Autoimmune kidney disease","IgAN (immunoglobulin A nephropathy)","B-cell modulation","BAFF/APRIL inhibition","Primary membranous nephropathy","Focal segmental glomerulosclerosis","Minimal change disease"]
Fundamentals
- Price$42.45 as of 2026-07-09 close
- Market cap$3.0B as of 2026-07-10
- 1-year return+84.5% as of 2026-07-09 close
- ROE-74.9% as of 2026-07-10
- Debt / equity0.15 as of 2026-07-10
- Beta0.88 as of 2026-07-10
Key risks (from latest filing)
["Regulatory approval risk: FDA priority review PDUFA target date of July 7, 2026 is near-term; failure to obtain accelerated approval or unfavorable regulatory action could materially impact the company","Clinical trial risk: Secondary endpoint data on eGFR changes at 104 weeks in ORIGIN 3 is expected Q1 2027, and adverse safety or efficacy findings could impact commercial viability","Market adoption and competition risk: Success depends on market acceptance, pricing, reimbursement, and the emergence of competing therapies for autoimmune kidney diseases"]
Competitors & peers
- Chemocentryx
- Aurinia Pharmaceuticals
- Calliditas Therapeutics
- Apellis Pharmaceuticals
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.